IGHE and anaphylaxis: Also, patients with anaphylaxis had higher median IgE (p=0.02) and CM-sIgE (p=0.006), larger wheal diameters to CM in SPTs (p=0.001), higher cumulative provocative doses of OFCs (p=0.06, NS), more adverse reactions (p=0.04) and a higher number of reactions during the oral immunotherapy (p=0.01), and longer mean duration of the build-up phase (p=0.03) compared with patients without anaphylaxis (Table 6).